Welcome to our dedicated page for DANAHER /DE/ SEC filings (Ticker: DHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DANAHER /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DANAHER /DE/'s regulatory disclosures and financial reporting.
Danaher reported second quarter 2026 results from continuing operations with sales of $6.3 billion, up 5.5% year-over-year. Non-GAAP core revenue grew 3.0% and 4.5% excluding respiratory testing. Net earnings were $870 million, or $1.23 per diluted share, up 60% year-over-year. Adjusted diluted EPS (non-GAAP) rose 8.0% to $1.94 after excluding amortization of acquisition-related intangible assets, Masimo-related acquisition items and other adjustments detailed in the reconciliation. Management highlighted particularly strong performance in Life Sciences and mid-teens bioprocessing order growth despite project-timing headwinds.
Operating cash flow was $1.5 billion and free cash flow $1.3 billion, both higher than the prior year and exceeding net earnings. For third quarter 2026, Danaher anticipates non-GAAP core revenue growth of 2.0%–3.0%; for full year 2026 it expects 3.0%–4.0% growth and raised its adjusted diluted EPS guidance to $8.45–$8.60 from $8.35–$8.55. The company completed its Masimo acquisition earlier than anticipated and, through Leica Biosystems, plans to acquire StatLab, a histology products business with approximately $250 million of 2025 revenue that is expected to grow at a high-single-digit core rate and be accretive to adjusted EPS in the first full year after a targeted 2026 close.
Danaher Corp (DHR) executive Christopher Bouda, VP and Chief Accounting Officer, reported a Form 4 showing a tax-withholding disposition of 60 shares of common stock at $200.79 per share for payment of exercise price or tax liability, leaving 9,107 shares held directly. He also reported 679.101 shares held indirectly through a 401(k) plan.
Danaher Corp. director Linda Filler reported equity compensation-related transactions in Danaher common stock. On July 15, 2026, she exercised options for 3,298 shares at an exercise price of $71.88 per share, classified as a derivative exercise. In connection with this, 1,181 shares were disposed of as a tax-withholding disposition at $200.79 per share, rather than through an open-market sale.
After these transactions, Filler directly holds 26,829.403 common shares of Danaher and indirectly holds 21,590 shares through a trust. The option position used for this exercise, covering 3,298 shares, was reduced to zero, reflecting full exercise of that specific director stock option grant.
Danaher director Elias A. Zerhouni exercised director stock options to acquire 3,298 common shares at an exercise price of $71.8800 per share. 1,181 shares were used in a tax-withholding disposition at $200.7900 per share. After these transactions he holds 46,484.2820 shares directly and 7,500.0000 shares indirectly through an LLC.
Danaher Corporation has created new long-term debt through a private placement of multiple Swiss franc–denominated senior notes issued by wholly owned subsidiary DH Masi Finance Inc. and guaranteed by Danaher. The company sold CHF 119,500,000 of 1.65% Series A Notes due June 3, 2031 and CHF 137,410,000 of 1.88% Series B Notes due June 3, 2033, alongside larger tranches maturing between 2036 and 2056 at fixed interest rates ranging from 2.10% to 2.51% per year. Interest is payable semi-annually on June 3 and December 3, starting December 3, 2026. Net proceeds are expected to be used for general corporate purposes, including working capital, acquisitions and share repurchases.
Danaher Corporation director Linda Filler reported new equity awards and updated holdings. She received 680 shares of common stock as a grant reported in Table I, and 1,699 director stock options with a conversion price of $161.9100 per share, expiring on May 15, 2036.
According to the footnote, these 680 units are restricted stock units payable solely in common stock. They vest on the earlier of the first anniversary of the grant date or immediately before the next annual shareholder meeting, with shares issued on the earlier of the director’s death or the first day of the seventh month after retirement from the Board.
After these awards, Filler directly holds 24,712.403 common shares and 1,699 options, and indirectly holds 21,590 common shares through a trust. The filing reflects equity awards rather than open-market buying or selling.
Danaher Corporation senior vice president Georgeann Couchara reported a small tax-related share disposition. On this Form 4, 281 shares of Danaher common stock were delivered at a price of $161.91 per share to satisfy tax obligations. After this non‑market tax-withholding transaction, she directly holds 8,291 common shares.
Danaher Corporation director Raymond C. Stevens reported equity awards rather than open-market trades. He received 680 restricted stock units that are payable solely in common stock, reported as common shares. These RSUs vest on the earlier of the first anniversary of the grant date or the next annual shareholder meeting.
Stevens was also granted director stock options on 1,699 underlying common shares at an exercise price of $161.91 per share, expiring on May 15, 2036. Following these awards, he directly holds 13,728.286 shares of common stock and 1,699 director stock options. The underlying RSU shares will not be issued until the earlier of his death or several months after retirement from the Board.